NCT02170116已完成1 期
Pharmacodynamics, Safety and Pharmacokinetics After Single Oral Administration of 10, 30, 100, 200 and 400 mg BIBR 1048 MS as Drinking Solution in Healthy Subjects. An Open Study, Placebo Randomized Double Blind at Each Dose Level.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 主要终点
- Changes from baseline in prothrombin time (PT) (International Normalised Ratio (INR))
研究概览
简要总结
The objective of this study was to assess safety, pharmacokinetics and the effect of BIBR 953 ZW on coagulation parameters of BIBR 953 ZW after oral single doses of the prodrug, BIBR 1048 MS, in healthy male subjects. This was the first administration of this substance to humans.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects as determined by results of screening
- •Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
- •Age >= 18 and <= 45 years
- •Broca >= - 20 % and <= + 20 %
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- •History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
- •History of orthostatic hypotension, fainting spells or blackouts
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
- •Chronic or relevant acute infections
- •History of
- •allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •any bleeding disorder including prolonged or habitual bleeding
- •other hematologic disease
- •cerebral bleeding (e.g. after a car accident)
- •commotion cerebri
- •Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
- •Use of any drugs which might influence the results of the trial within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within 2 months prior to administration or during trial
- •Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
- •Alcohol abuse (> 60 g/day)
- •Drug abuse
- •Blood donation within 1 month prior to administration or during the trial
- •Excessive physical activities within 5 days prior to administration or during the trial
- •Any laboratory value outside the clinically accepted reference range
- •History of any familial bleeding disorder
- •Thrombocytes < 150000/µl
研究组 & 干预措施
BIBR 1048 MS dose 5
Experimental
干预措施: BIBR 1048 MS dose 5 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo to BIBR 1048 MS (Drug)
BIBR 1048 MS dose 1
Experimental
干预措施: BIBR 1048 MS dose 1 (Drug)
BIBR 1048 MS dose 2
Experimental
干预措施: BIBR 1048 MS dose 2 (Drug)
BIBR 1048 MS dose 3
Experimental
干预措施: BIBR 1048 MS dose 3 (Drug)
BIBR 1048 MS dose 4
Experimental
干预措施: BIBR 1048 MS dose 4 (Drug)
结局指标
主要结局
Changes from baseline in prothrombin time (PT) (International Normalised Ratio (INR))
时间窗: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after administration
Changes from baseline in activated partial thromboplastin time (aPTT)
时间窗: - 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours after administration
次要结局
- Changes from baseline in Ecarin Clotting Time (ECT)(up to day 3)
- Changes from baseline in Pulse rate(up to day 3)
- Peak (maximum) plasma concentration (Cmax) of BIBR 953 ZW(- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration)
- time to reach the peak plasma concentration (tmax ) of BIBR 953 ZW(- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration)
- AUC0-12 h - Area under the plasma concentration-time curve of BIBR 953 ZW from 0 to 12 h(- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration)
- Area under the plasma concentration-time curve (AUC0-infinity) of BIBR 953 ZW from 0 to infinity(- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration)
- Area under the plasma concentration-time curve of BIBR 953 ZW (AUCtf -infinity) from tf (last time point when measured plasma concentration) to infinity expressed as % of AUC0-infinity(- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration)
- Terminal half-life(t1/2 ) of BIBR 953 ZW derived from non-compartmental analysis(- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration)
- Total mean residence time (MRTtot ) of BIBR 953 ZW(- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration)
- Total clearance (CLtot /f ) of BIBR 953 ZW after oral administration(24 hours after administration)
- Volume of distribution (Vz/f ) of BIBR 953 ZW during terminal phase after oral administration(- 0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration)
- Changes from baseline in Systolic and diastolic blood pressure(up to day 3)
- Occurrence of Adverse events(up to day 3)
- Changes from baseline in thrombin time(up to day 3)
- Changes from baseline in thrombin inhibition test time(up to day 3)
研究者
相似试验
已完成
1 期
BIBR 953 ZW in Healthy Elderly SubjectsHealthyNCT02173730Boehringer Ingelheim36
已完成
1 期
Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy SubjectsHealthyNCT02182037Boehringer Ingelheim56
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian OriginHealthyNCT02170844Boehringer Ingelheim40
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human SubjectsHealthyNCT02211157Boehringer Ingelheim24
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human SubjectsHealthyNCT02208856Boehringer Ingelheim64